Last reviewed · How we verify

Fexofenadine, Comparator = Montelukast

Sanofi · Phase 3 active Small molecule

Fexofenadine, Comparator = Montelukast is a Selective H1-receptor antagonist (second-generation antihistamine) Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Allergic rhinitis (seasonal and perennial), Chronic urticaria.

Fexofenadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses without crossing the blood-brain barrier.

Fexofenadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses without crossing the blood-brain barrier. Used for Allergic rhinitis (seasonal and perennial), Chronic urticaria.

At a glance

Generic nameFexofenadine, Comparator = Montelukast
SponsorSanofi
Drug classSelective H1-receptor antagonist (second-generation antihistamine)
TargetH1 histamine receptor
ModalitySmall molecule
Therapeutic areaImmunology / Allergy
PhasePhase 3

Mechanism of action

Fexofenadine competitively binds to peripheral H1 histamine receptors on mast cells and basophils, preventing histamine release and its downstream effects on smooth muscle contraction, vasodilation, and itching. Unlike first-generation antihistamines, it is highly selective for peripheral H1 receptors and does not significantly penetrate the central nervous system, resulting in minimal sedation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Fexofenadine, Comparator = Montelukast

What is Fexofenadine, Comparator = Montelukast?

Fexofenadine, Comparator = Montelukast is a Selective H1-receptor antagonist (second-generation antihistamine) drug developed by Sanofi, indicated for Allergic rhinitis (seasonal and perennial), Chronic urticaria.

How does Fexofenadine, Comparator = Montelukast work?

Fexofenadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses without crossing the blood-brain barrier.

What is Fexofenadine, Comparator = Montelukast used for?

Fexofenadine, Comparator = Montelukast is indicated for Allergic rhinitis (seasonal and perennial), Chronic urticaria.

Who makes Fexofenadine, Comparator = Montelukast?

Fexofenadine, Comparator = Montelukast is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

What drug class is Fexofenadine, Comparator = Montelukast in?

Fexofenadine, Comparator = Montelukast belongs to the Selective H1-receptor antagonist (second-generation antihistamine) class. See all Selective H1-receptor antagonist (second-generation antihistamine) drugs at /class/selective-h1-receptor-antagonist-second-generation-antihistamine.

What development phase is Fexofenadine, Comparator = Montelukast in?

Fexofenadine, Comparator = Montelukast is in Phase 3.

What are the side effects of Fexofenadine, Comparator = Montelukast?

Common side effects of Fexofenadine, Comparator = Montelukast include Headache, Nausea, Dyspepsia, Fatigue, Dizziness.

What does Fexofenadine, Comparator = Montelukast target?

Fexofenadine, Comparator = Montelukast targets H1 histamine receptor and is a Selective H1-receptor antagonist (second-generation antihistamine).

Related